Janux Therapeutics Enters $850 Million Collaboration and Exclusive License Agreement with Bristol Myers Squibb to Develop Tumor-Activated Therapeutics

Janux Therapeutics Enters $850 Million Collaboration and Exclusive License Agreement with Bristol Myers Squibb to Develop Tumor-Activated Therapeutics — alphai